Home › Trial NCT07829588
Pharmacokinetic (PK) Study of QL1203 and Vectibix® for the Treatment of RAS Wild-type Metastatic Colorectal Cancer
- Trial IDNCT07829588
- StatusNot Yet Recruiting
- PhasePhase 1
- Study typeInterventional
- SponsorQilu Pharmaceutical Co., Ltd.
- Enrollment136
- Start date2026-11-24
- ConditionsRAS Wild-type Metastatic Colorectal Cancer
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.